MEDIculous REMeDy Metabolic disease heterogeneity definition, prevention and remission with targeted interventions
- Coordinator
- Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH, Germany
- Runs
- 1 January 2027 to 31 December 2030
- Status
- Running
- EU funding
- €4.4m
- Total cost
- —
- Partners
- 31 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311734
What the project is doing
In the project's own words, from its summary on CORDIS.
Obesity, diabetes and associated complications constitute a rapidly escalating scientific and societal challenge across Europe marked by profound heterogeneity in causes, clinical trajectories and treatment responses. This heterogeneity explains the limited effectiveness of standardized therapies and highlights the need to stratify metabolic disease. To confront this challenge, MEDIculous REMeDy brings together a pan-European, interdisciplinary doctoral network spanning academia, healthcare, industry, public and patient organizations.
The network’s first objective is to train critical and entrepreneurial metabolic health researchers through innovative interdisciplinary, translational and intersectoral training focused on tailored career development, transferable skills and leadership. Gender-responsive research design, open science, public and patient engagement underpin this training culture, equipping DCs with essential skills for academic and non-academic careers.
These early-career researchers will drive – and be shaped by – our scientific objectives: (1) to map metabolic disease heterogeneity across the full disease spectrum from early metabolic dysfunction and obesity to advanced diabetes with complications, and (2) to dissect this heterogeneity from underlying molecular mechanisms to biomarkers, therapeutic targets and treatment responses. To achieve its scientific objectives, the consortium will integrate metabolic medicine and computational systems biology that draw on multi-country European patient cohorts, advanced human in vitro platforms and complementary in vivo disease models.
This novel integrative strategy enables the development of robust patient stratification and personalized therapeutic approaches applicable across European populations, pushing precision medicine forward. By uniting scientific excellence, pioneering training and societal relevance, MEDIculous REMeDy transforms metabolic disease research and precision medicine across Europe.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Coordinator |
| Ohmx.bio | Gent | Belgium | Associatedpartner |
| The Governors of the University of Alberta | Edmonton | Canada | Associatedpartner |
| Deutsches Museum Von Meisterwerken Der Naturwissenschaft Und Technik | Munchen | Germany | Associatedpartner |
| Deutsches Zentrum für Diabetesforschung e.V. | Oberschleiheim | Germany | Associatedpartner |
| European Association for the Study of Diabetes (easd) E. V. | Dusseldorf | Germany | Associatedpartner |
| Evotec International GmbH | Hamburg | Germany | Associatedpartner |
| Klinikum Der Technischen Universität München (tum Klinikum) | Muenchen | Germany | Associatedpartner |
| Technische Universitaet Muenchen | Muenchen | Germany | Associatedpartner |
| Universitaet Leipzig | Leipzig | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Kobenhavns Universitet | Kobenhavn | Denmark | Participant |
| Fecundis Lab S.l. | Sant Cugat Del Valles | Spain | Associatedpartner |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Universidad Autonoma De Madrid | Madrid | Spain | Participant |
| Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea | Leioa | Spain | Associatedpartner |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Diabetesseura T1D ry | Helsinki | Finland | Associatedpartner |
| Helsingin Yliopisto | Helsinki | Finland | Participant |
| Turun Yliopisto | Turku | Finland | Associatedpartner |
| Genos Glycoscience Doo Za Istrazivanje I Usluge | Osijek | Croatia | Participant |
| Sveuciliste U Zagrebu Medicinski Fakultet | Zagreb | Croatia | Associatedpartner |
| Enamine PL Sp. z o.o. | Wrocaw | Poland | Associatedpartner |
| Sanprobi Spolka Z Ograniczona Odpowiedzialnoscia Spolka Komandytowa | Szczecin | Poland | Associatedpartner |
| Warszawski Uniwersytet Medyczny | Warszawa | Poland | Participant |
| Universitatea De Vest Din Timisoara | Timisoara | Romania | Participant |
| Kemijski Institut | Ljubljana | Slovenia | Participant |
| Univerza V Ljubljani | Ljubljana | Slovenia | Associatedpartner |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Participant |
| Ignota Labs Limited | Cambridge | United Kingdom | Associatedpartner |
| The University of Exeter | Exeter | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI